Form 8-K - Current report:
SEC Accession No. 0001493152-24-036855
Filing Date
2024-09-17
Accepted
2024-09-17 16:15:52
Documents
18
Period of Report
2024-09-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43924
2 ex1-1.htm EX-1.1 350213
3 ex4-1.htm EX-4.1 106542
4 ex4-2.htm EX-4.2 100035
5 ex99-1.htm EX-99.1 13645
  Complete submission text file 0001493152-24-036855.txt   911419

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE kapa-20240916.xsd EX-101.SCH 3027
7 XBRL LABEL FILE kapa-20240916_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE kapa-20240916_pre.xml EX-101.PRE 24173
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3799
Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

EIN.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42275 | Film No.: 241304613
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)